Sign in
NBTX Stock Price, Chart, Stats & News
Nanobiotix S.A.
Save
1.74B
Market cap
–
Current P/E
96.15x
Forward P/E
NBTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -765.37% |
Pretax margin | -900.35% |
Net margin | -899.70% |
Effective tax rate | 0.07% |
ROA | -114.32% |
ROE | 76.70% |
D/E | -0.74x |
Interest coverage ratio | -3.74x |
NBTX valuation
P/E | – |
P/S | 218.78x |
P/B | -17.85x |
P/CF | -39.54x |
P/FCF | -39.70x |
P/OCF | -39.54x |
PEG | -1.13x |
EV multiple | -36.29x |
About
Nanobiotix S. A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Similar securities
Based on sector and market capitalization
Report issue